MedTrace Logo

Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer

NCT01077986 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2021-04-21

No results posted yet for this study

Summary

In this study the investigators want to determine the activity and safety of concurrent interruption of the MAPK and PI3K pathways by EGFR and mTOR inhibition in patients with metastatic pancreatic cancer.

Conditions

Interventions

DRUG

Capecitabine

Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.

DRUG

Cetuximab

Cetuximab will be administered weekly, starting at day 8.

DRUG

Everolimus

Everolimus will be administered daily, starting on day 1.

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    lead OTHER

Principal Investigators

  • Hanneke Wilmink, MD PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2010-08-31
Completion
2011-08-31

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01077986 on ClinicalTrials.gov